Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c.

Autor: Gunasena M; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA., Shukla RK; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA., Yao N; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.; Jilin Agricultural University, Changchun, Jilin, China., Rosas Mejia O; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA., Powell MD; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA., Oestreich KJ; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA., Aceves-Sánchez MJ; Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Av. Normalistas 800, Col. Colinas de la Normal, 44270, Guadalajara, Mexico., Flores-Valdez MA; Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Av. Normalistas 800, Col. Colinas de la Normal, 44270, Guadalajara, Mexico. floresv@ciatej.mx., Liyanage NPM; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA. Namal.MalimbadaLiyanage@osumc.edu.; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA. Namal.MalimbadaLiyanage@osumc.edu., Robinson RT; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA. richard.robinson@osumc.edu.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Jul 20; Vol. 12 (1), pp. 12377. Date of Electronic Publication: 2022 Jul 20.
DOI: 10.1038/s41598-022-14935-y
Abstrakt: The vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the BCG deletion mutant and vaccine candidate BCGΔBCG1419c was demonstrated to survive longer in intravenously infected BALB/c mice due to enhanced biofilm formation, and better protected both BALB/c and C57BL/6 mice against TB-induced lung pathology during chronic stages of infection, relative to BCG controls. BCGΔBCG1419c-elicited protection also associated with lower levels of proinflammatory cytokines (i.e. IL6, TNFα) at the site of infection in C57BL/6 mice. Given the distinct immune profiles of BCG- and BCGΔBCG1419c-immunized mice during chronic TB, we set out to determine if there are early immunological events which distinguish these two groups, using multi-dimensional flow cytometric analysis of the lungs and other tissues soon after immunization. Our results demonstrate a number of innate and adaptive response differences between BCG- and BCGΔBCG1419c-immunized mice which are consistent with the latter being longer lasting and potentially less inflammatory, including lower frequencies of exhausted CD4 + T helper (T H ) cells and higher frequencies of IL10-producing T cells, respectively. These studies suggest the use of BCGΔBCG1419c may be advantageous as an alternative TB vaccine candidate.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje